Halozyme Therapeutics Inc. (HALO)
HALO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$109.62
-1.31% on the day
Market cap
$12.4B
Large cap
Revenue · 2025
$1.4B
+37.6% on 2024
Net income · 2025
$316.9M
22.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | HALO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001159036 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.4B |
| Net income | $316.9M |
| Operating income | $469.0M |
| Net margin | 22.7% |
| Operating margin | 33.6% |
| Revenue growth | +37.6% |
| Cash | $133.8M |
| Total assets | $2.5B |
| P/E (computed) | 39.3× |
| P/S (computed) | 8.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2017-05-19 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-30 |
| Latest proxy | DEFA14A | 2026-03-23 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.4% |
| 1 month | +9.9% |
| 3 months | +50.7% |
| Year to date | +73.6% |
| 1 year | +78.8% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
| PCVX | Vaxcyte Inc. | $66.80 | -5.45% | $10.5B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| IBRX | ImmunityBio Inc. | $9.80 | -3.16% | $10.4B |
| TWST | Twist Bioscience Corporation | $151.33 | -0.35% | $10.0B |
| KRYS | Krystal Biotech Inc. | $321.16 | -3.29% | $9.5B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier